Cuprina Holdings, a Singapore-based provider of chronic wound care products, filed on Thursday with the SEC to raise up to $10 million in an initial public offering.
Cuprina is focused on the development and commercialization of products for the management of chronic wounds, with plans to expand into cosmeceutical products in the future. The company currently manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name. In addition to the MEDIFLY products, the company has two lines of chronic wound care products in its pipeline, and currently expects development to take place over the course of 2024 and 2025. Cuprina has been selling its MEDIFLY products primarily in Singapore since 2020 and expanded into Hong Kong in 2023. It plans to further expand into Southeast Asia, the Middle East, and mainland China in 2024 and 2025.
The Singapore-based company was founded in 2019 and plans to list on the Nasdaq under the symbol CUPR. Cuprina Holdings filed confidentially on October 13, 2023. Network 1 Financial Securities is the sole bookrunner on the deal. No pricing terms were disclosed.
